Photodynamic therapy approved in UK:
This article was originally published in Clinica
Canadian company QLT PhotoTherapeutics has been granted marketing clearance in the UK for Photofrin (porfimer sodium), its light-activated drug treatment for late-stage lung cancer and oesophageal cancer. The drug is already available in France, Germany and the Netherlands where it is being marketed by the Vancouver-based company's partner Beafour Ipsen. It is also awaiting US approval after being backed by an FDA advisory panel in September 1998 (Clinica No 824, p 13). Photofrin is activated by non-thermal laser light produced by instruments available from a number of companies. In Europe these include lasers developed for photodynamic therapy by Laserscope, Coherent Medical Group and Diomed.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.